Triple targeted therapy is a new perspective treatment strategy for patients with FLT3-mutated acute myeloid leukemia. the literature review and single-centre experience
| Autor: | A. E. Prokopyev, A. A. Shatilova, I. G. Budaeva, A. I. Reshetova, R. Sh. Badaev, D. V. Motorin, K. A. Kovalchuk, A. E. Ershova, E. N. Tochenaya, V. V. Ivanov, K. V. Bogdanov, Yu. V. Mirolyubova, E. V. Tolstopyatova, T. S. Nikulina, Yu. A. Alekseeva, L. L. Girshova |
|---|---|
| Rok vydání: | 2022 |
| Zdroj: | Russian Journal for Personalized Medicine. 2:63-76 |
| ISSN: | 2782-3814 2782-3806 |
| Popis: | Internal tandem duplication is the most common form of mutation in FMS-like tyrosine kinase 3 (FLT3) in different haematological malignancies, highlighting in acute myeloid leukaemia (AML) and is associated with increased risk of relapse and reduced overall survival. A major breakthrough in the treatment of FLT3-mutated AML has been achieved through the use of highly selective FLT3 tyrosine kinase inhibitors, both in monotherapy and in combination with standard intensive cytotoxic chemotherapy. The desire to improve the outcomes of patients with AML, including those with relapse and refractory disease, has led to attempts to use non-standard therapeutic options. Enhancement of the antileukemic effects of the second-generation FLT3 inhibitor Gilteritinib may be achieved through synergy with the hypomethylating agent 5-azacytidine and the selective Bcl-2 inhibitor Venetoclax. Thus, targeted triple therapy is a promising option in the treatment of patients with FLT3-mutated AML. This study sought to evaluate the effectiveness of “triple therapy” regimen in 4 patients with relapsed/refractory FLT3 mutated AML. We found that the use of this combination showed rapid response with good safety and frequently allowed subsequent transplant and achieve durable clinical benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|